fearless chemistry

Akhil Santhosh: Important changes in the latest ESMO BTC guidelines

Akhil Santhosh, Medical Oncology Specialist at MVR Cancer Centre & Research Institute, shared a post on X:

“Important changes in the latest ESMO BTC guidelines:

  1. Removal of Infigratinib in the FGFR rearranged setting.
  2. Inclusion of Zanidatamab (Herizon Btc 01) and Trastuzumab deruxtecan Destiny pan tumour 02 for Her2 amplified/overexpressed BTC.”

Akhil Santhosh: Important changes in the latest ESMO BTC guidelines

Akhil Santhosh BTC cancer Deruxtecan ESMO FGFR fight against cancer Global fight against cancer HER2 infigratinib MedOnc MVR Cancer Centre & Research Institute OncoDaily Oncology trastuzumab Zanidatamab